Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:23:00.535Z.
Consensus retrieved: 2026-10-06T16:46:11.814Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:23:00.535Z.
Quote observation: 2026-10-06T18:19:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d4773eeabafa62aebeff6315a1128d32b86b9098e0544dfe9acdb21c4fcfe70f
Forward PE Ratio (N/A) = Dated Quote Price ($2.23) / Consensus Forward EPS ($-0.35)
FORWARD PE RATIO
N/A
Neuronetics, Inc.
Market Cap
$155.14M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Neuronetics, Inc. (STIM) | $155.14M | N/A |
| LifeMD, Inc. (LFMDP)vs › | $154.79M | N/A |
| Inogen, Inc. (INGN)vs › | $157.72M | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $152.82M | N/A |
| PepGen Inc. (PEPG)vs › | $158.74M | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $159.14M | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $150.43M | N/A |
| Minerva Neurosciences, Inc. (NERV)vs › | $160.96M | N/A |
| Codexis, Inc. (CDXS)vs › | $149.51M | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.74M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.23, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.35 | $-0.35 – $-0.35 | 2 | n/m |
| 2027-12-31 | $-0.28 | $-0.28 – $-0.28 | 2 | n/m |
| 2028-12-31 | $-0.23 | $-0.28 – $-0.19 | 3 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
